News Search Results
May 05, 2026, 16:01 ET Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
2026.INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington's disease.R&D guidance reflects the continued advancement of the Company's pre-clinical and clinical portfolio including the Phase 3
More news about: Neurocrine Biosciences, Inc.
May 05, 2026, 09:00 ET Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
May 04, 2026, 12:00 ET Reworld™ Drives Local Environmental Impact Through Earth Month Initiatives
with a self-watering system for the school's rooftop garden.Huntington, New York: Reworld™ sponsored and participated in the Town of Huntington's Family Earth Day Celebration at Elwood Park, featuring live music, arts and crafts, free tree saplings, composting demos, and more.Lee
More news about: Reworld Holding Corporation
May 04, 2026, 08:30 ET Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
May 04, 2026, 07:30 ET Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
psychiatric, and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
May 01, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Apr 29, 2026, 16:05 ET Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known
More news about: Neurocrine Biosciences, Inc.
Apr 28, 2026, 16:05 ET PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to an external natural history cohort. "These results give us confidence in the potential for votoplam to deliver long-term meaningful effect on slowing Huntington's disease progression,"
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 09:28 ET PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
clinical trial, Novartis assumed responsibility for votoplam's development, manufacturing and commercialization.About Huntington's DiseaseHuntington's disease (HD) is a fatal, hereditary, genetic disorder of the central nervous system.1 It is caused by a defective gene.
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 07:00 ET Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting
supporting MSH3 splice modulation as a potential therapeutic strategy for repeat expansion disorders, a broad group of genetic disorders including Huntington's disease, spinocerebellar ataxia, myotonic dystrophy, and others. It highlights a novel targeted RNA approach designed to modulate disease-driving
More news about: Ascidian Therapeutics
Apr 23, 2026, 06:30 ET Huntington Bancshares Incorporated Reports 2026 First-Quarter Earnings
Call / Webcast InformationHuntington's senior management will host an earnings conference call on April 23, 2026, at 9:00 a.m. (Eastern Time). The call may be accessed via a live Internet webcast at the Investor Relations section of Huntington's website,
More news about: Huntington Bancshares Incorporated
Apr 22, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Apr 21, 2026, 16:30 ET Huntington Bank Expands Commercial Banking into Austin
The commercial expansion follows Huntington's significant growth in Texas, including the recent acquisitions of Houston-based Cadence Bank and Dallas-based Veritex Bank. With Cadence and Veritex,
More news about: Huntington Bancshares Incorporated
Apr 21, 2026, 10:00 ET Huntington Bank Awards 70 Charlotte-area Educators with Year-long Professional Development Experience
Educators from Anson, Mecklenburg and Union counties selected to participate in Huntington's Ignite the Classroom InitiativeCHARLOTTE, N.C., April 21, 2026 /PRNewswire/ -- Seventy educators from
More news about: Huntington Bank
Apr 20, 2026, 10:00 ET Huntington Bank Named West Virginia University Campus Banking Partner
New partnership offers a variety of benefits to WVU community and deepens Huntington's investment in West VirginiaMORGANTOWN, W.Va., April 20, 2026 /PRNewswire/ -- The Huntington National Bank (Huntington)
More news about: Huntington Bank
Apr 16, 2026, 11:13 ET Huntington Bank Surpasses $50 Million Raised for Pelotonia
Bank today announced it has surpassed $50 million raised in support of Pelotonia, becoming Pelotonia's largest all-time supporter and reinforcing Huntington's commitment to advancing life-saving cancer research.
More news about: Huntington Bank
Apr 15, 2026, 16:45 ET Huntington Bancshares Incorporated Announces First Quarter 2026 Earnings Call Details
at 9 a.m. ET.Webcast InformationInterested investors may access the live audio webcast in the investor relations section of Huntington's website (
More news about: Huntington Bancshares Incorporated
Apr 14, 2026, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Apr 14, 2026, 09:00 ET Wing 2 Wing Foundation Renews $60,000 Commitment to Fairfield U Mentor Program, Advancing Opportunity for Huntington's Next Generation
announce a renewed $60,000 donation from the Wing 2 Wing Foundation, led by Brad and Alys Smith, marking a continued investment in the future of Huntington's youth and the next generation of leaders.
More news about: Wing 2 Wing Foundation
Apr 14, 2026, 08:30 ET Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known
More news about: Neurocrine Biosciences, Inc.
Apr 12, 2026, 13:31 ET QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Apr 07, 2026, 04:00 ET QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Apr 06, 2026, 10:00 ET Huntington Bank Named Official Consumer Bank of the University of Michigan
card, to their Huntington account. This allows the MCard to be used as a debit card.Mortgage closing cost discounts, as well as access to Huntington's full suite of products and services.Convenient local banking with the addition of six ATMs on the university's campus, including one in
More news about: Huntington Bancshares Incorporated
Apr 06, 2026, 07:00 ET Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
therapies: INGREZZA®, the vesicular monoamine transmitter 2 (VMAT2) market leader for the treatment of tardive dyskinesia and the chorea associated with Huntington's disease, with $2.51 billion in 2025 revenue; CRENESSITY®, approved in December 2024 for the treatment of classic congenital adrenal hyperplasia
More news about: Neurocrine Biosciences, Inc.